Obesity

Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting.

Country-specific public health policies that target metabolic dysfunction-associated steatotic liver disease risk factors, such as food insecurity and physical activity, may play a key role in mitigating the global burden of disease.

The National Kidney Foundation launched a new interactive portal that lets patients with chronic kidney disease learn more about their condition, according to a press release.

A novel oral GLP-1 receptor agonist was well-tolerated and linked with weight loss compared with placebo in healthy adults with overweight or obesity, according to top-line results of a phase 1 study.

Bariatric surgery for weight loss was associated with improvements in blood pressure and antihypertensive use among patients with obesity compared with medical therapy and/or lifestyle management, a speaker reported.

The Healio news team won an APEX Grand Award for its Treating Obesity resource center, a collection of the latest news and perspectives on medications for obesity.

The FDA has cleared a tubeless automated insulin delivery system indicated for adults with type 2 diabetes.

Results from two studies found no association between the use of GLP-1 receptor agonists and increased risk for suicide, suicidal thoughts or depression, findings published in JAMA Internal Medicine showed.

Semaglutide cut the risk for worsening heart failure and CV death for adults with HF with preserved ejection fraction, according to data presented at the European Society of Cardiology Congress and simultaneously published in The Lancet.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.